PrimRNA

PrimRNA is a biotechnology company focused on developing a novel class of small molecule therapeutics that modulate the biogenesis of microRNAs. Spun out from the Wistar Institute, the company's platform targets the processing of primary microRNAs (pri-miRNAs) to selectively regulate gene expression. Their lead programs focus on inhibiting specific microRNAs, such as miR-21 and miR-10b, which are known drivers of tumor growth and metastasis. By utilizing small molecules to interfere with RNA-protein interactions, PrimRNA aims to address oncogenic pathways that are difficult to target with traditional protein-centric approaches. The company is currently in the pre-clinical stage, advancing its pipeline toward candidate selection.